公开(公告)号：EP2891499A1

公开(公告)日：2015-07-08

申请号：EP13832429.8

申请日：2013-08-30

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： KOJIMA, Naoki ,  ROMAN, J., Richard ,  MIYATA, Noriyuki ,  TAKAHASHI, Teisuke ,  TOMOIKE, Hideki ,  TAKEDA, Takuya

IPC分类号： A61K45/06 ,  A61K31/382 ,  A61K31/401 ,  A61K31/41 ,  A61P9/12 ,  A61P31/10

CPC分类号： A61K31/382 ,  A61K31/40 ,  A61K31/401 ,  A61K31/41 ,  A61K45/06 ,  A61K2300/00

摘要： Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function.

摘要翻译： 提供依赖于SGLT 2抑制剂和抗高血压药物组合的药物，其可用于治疗涉及至少高血压或糖尿病的疾病作为心血管事件的危险因素，以及治疗疾病的方法。 由于本发明显示出通过任何单一抗高血压药物无法获得的优异的降血压作用，因此可以解决与使用两种或更多种抗高血压药物相关联以将血压降低到所需水平的常规问题。 此外，本发明显示出在糖尿病，与糖尿病相关的疾病或糖尿病并发症，特别是糖尿病性肾病中的显着治疗功效。 作为另外的优点，本发明也可用于治疗涉及肾功能降低的疾病。